{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:52:30Z","timestamp":1784872350167,"version":"3.55.0"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,13]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The rate of incidence of metabolic dysfunction-related fatty liver disease (MAFLD) has rapidly increased globally in recent years, but early diagnosis is still a challenge. The purpose of this systematic review and meta-analysis is to identify visfatin for early diagnosis of MAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We strictly adhered to the relevant requirements of Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The systematic search was conducted in 7 sources (PubMed, Embase, Cochrane Library, CNKI, Wanfang, CBM, and ClinicalTrials.gov) until February 2024. The meta-analysis was performed using Stata 12. Outcomes were expressed in the form of standardized mean difference (SMD) and 95% confidence interval and were analyzed using meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The results showed that there was no significant difference in circulating visfatin levels between patients with MAFLD and controls (SMD\u2005=\u20050.13 [\u22120.34, 0.60]). However, the outcomes indicated that the level of circulating visfatin was significantly higher in MAFLD patients in the Middle Eastern subgroup (SMD\u2005=\u20050.45 [0.05, 0.85]) and in the obese patient subgroup (SMD\u2005=\u20051.05 [0.18, 1.92]). No publication bias was detected, and sensitivity analysis confirmed the stability of the outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The serum visfatin levels of MAFLD patients did not differ significantly from those of controls. However, visfatin concentrations in serum were statistically higher within Middle Eastern or obese MAFLD patients compared to controls. There is a need for further research to investigate visfatin\u2019s potential as a biomarker for MAFLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000039613","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T13:20:13Z","timestamp":1726579213000},"page":"e39613","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Association of circulating visfatin level and metabolic fatty liver disease: An updated meta-analysis and systematic review"],"prefix":"10.1097","volume":"103","author":[{"given":"Shuaihang","family":"Chen","sequence":"first","affiliation":[{"name":"The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaihan","family":"Wu","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yani","family":"Ke","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"He","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenlu","family":"Shen","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qicong","family":"Li","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Ruan","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhu","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keying","family":"Du","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Liu","sequence":"additional","affiliation":[{"name":"Center of Clinical Evaluation, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260203","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact.","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol"},{"key":"R2-20260203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R3-20260203","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"R4-20260203","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","article-title":"Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 Individuals.","volume":"107","author":"Chan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R5-20260203","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2012.10.001","article-title":"Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.","volume":"10","author":"White","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R6-20260203","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3390\/ijms21041525","article-title":"Molecular mechanisms: connections between nonalcoholic fatty liver disease, steatohepatitis and hepatocellular carcinoma.","volume":"21","author":"Kanda","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"Suppl 2","key":"R7-20260203","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14521","article-title":"A clinical overview of non-alcoholic fatty liver disease: a guide to diagnosis, the clinical features, and complications-what the non-specialist needs to know.","volume":"24","author":"Muthiah","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"R8-20260203","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"key":"R9-20260203","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications.","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"R10-20260203","doi-asserted-by":"crossref","first-page":"154433","DOI":"10.1016\/j.metabol.2020.154433","article-title":"MAFLD and risk of CKD.","volume":"115","author":"Sun","year":"2021","journal-title":"Metabolism"},{"key":"R11-20260203","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000519611","article-title":"Diagnostic and therapy of nonalcoholic fatty liver disease: a narrative review.","volume":"38","author":"Roeb","year":"2022","journal-title":"Visc Med"},{"key":"R12-20260203","first-page":"1431","article-title":"Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor.","volume":"14","author":"Samal","year":"1994","journal-title":"Mol Cell Biol"},{"key":"R13-20260203","doi-asserted-by":"crossref","first-page":"518","DOI":"10.5603\/GP.a2018.0088","article-title":"The role of visfatin in pathogenesis of gestational diabetes (GDM).","volume":"89","author":"Radzicka","year":"2018","journal-title":"Ginekol Pol"},{"key":"R14-20260203","doi-asserted-by":"crossref","first-page":"155193","DOI":"10.1016\/j.cyto.2020.155193","article-title":"The up-regulation of markers of adipose tissue fibrosis by visfatin in pre-adipocytes as well as obese children and adolescents.","volume":"134","author":"Ezzati-Mobaser","year":"2020","journal-title":"Cytokine"},{"key":"R15-20260203","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/13813455.2018.1518987","article-title":"Serum visfatin and adiponectin - markers in women with polycystic ovarian syndrome.","volume":"126","author":"Bannigida","year":"2020","journal-title":"Arch Physiol Biochem"},{"key":"R16-20260203","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jcla.21491","article-title":"Visfatin levels in nonalcoholic fatty liver disease.","volume":"26","author":"Akbal","year":"2012","journal-title":"J Clin Lab Anal"},{"key":"R17-20260203","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1665-2681(19)31635-7","article-title":"Visceral adipose tissue visfatin in nonalcoholic fatty liver disease.","volume":"9","author":"Gaddipati","year":"2010","journal-title":"Ann Hepatol"},{"key":"R18-20260203","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.3390\/jcm10143029","article-title":"Serum visfatin levels in nonalcoholic fatty liver disease and liver fibrosis: systematic review and meta-analysis.","volume":"10","author":"Ismaiel","year":"2021","journal-title":"J Clin Med"},{"key":"R19-20260203","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R20-20260203","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R21-20260203","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range.","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"R22-20260203","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range.","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"R23-20260203","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1177\/09622802231172043","article-title":"Detecting the skewness of data from the five-number summary and its application in meta-analysis.","volume":"32","author":"Shi","year":"2023","journal-title":"Stat Methods Med Res"},{"key":"R24-20260203","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1348\/000711007X255327","article-title":"Fixed-versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results.","volume":"62","author":"Schmidt","year":"2009","journal-title":"Br J Math Stat Psychol"},{"key":"R25-20260203","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ajodo.2021.12.002","article-title":"An introduction to cumulative meta-analysis.","volume":"161","author":"Spineli","year":"2022","journal-title":"Am J Orthod Dentofacial Orthop"},{"key":"R26-20260203","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R27-20260203","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S0168-8278(06)80717-8","article-title":"Circulating and adipose tissue expression of visfatin in non-alcoholic fatty liver disease.","volume":"44","author":"Soardol","year":"2006","journal-title":"J Hepatol"},{"key":"R28-20260203","first-page":"19","article-title":"Association of serum Acrp30 and Visfatin with liver fibrosis of nonalcoholic disease of fatty liver.","volume":"48","author":"Pan","year":"2008","journal-title":"Shandong Medicine"},{"key":"R29-20260203","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1007\/s11695-008-9506-y","article-title":"A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).","volume":"18","author":"Younossi","year":"2008","journal-title":"Obes Surg"},{"key":"R32-20260203","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1210\/jc.2009-2148","article-title":"Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease.","volume":"95","author":"Dahl","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R33-20260203","first-page":"532","article-title":"Association between plasma visfatin and insulin sensitivity in patients with newly diagnosed type 2 diabetes and non-alcoholic disease of fatty liver (NAFLD).","volume":"19","author":"Pan","year":"2011","journal-title":"Chin J Diabetes"},{"key":"R34-20260203","first-page":"337","article-title":"Changes and significance of serum visfatin levels in obesity and nonalcoholic disease of fatty liver.","volume":"40","author":"Tian","year":"2011","journal-title":"J China Med Univ"},{"key":"R35-20260203","first-page":"735","article-title":"Relationship between serum visfatin and serum adiponectin level and the pathology of nonalcoholic disease of fatty liver.","volume":"27","author":"Zhu","year":"2011","journal-title":"J Clin Hepatobiliary Dis"},{"key":"R36-20260203","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.clinbiochem.2012.11.006","article-title":"Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease.","volume":"46","author":"Auguet","year":"2013","journal-title":"Clin Biochem"},{"key":"R37-20260203","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S1665-2681(19)31338-9","article-title":"Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.","volume":"12","author":"Genc","year":"2013","journal-title":"Ann Hepatol"},{"key":"R38-20260203","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1665-2681(19)31316-X","article-title":"Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: introduction of CHA index.","volume":"12","author":"Polyzos","year":"2013","journal-title":"Ann Hepatol"},{"key":"R39-20260203","first-page":"510","article-title":"Relationship between adiponectin leptin and insulin resistance with non-alcoholic disease of fatty liver.","volume":"19","author":"Chen","year":"2013","journal-title":"Hebei Medicine"},{"key":"R40-20260203","first-page":"67","article-title":"The study of relationship between the levels of serum visfatin, IL-6 and insulin resistance in the patients with nonalcoholic disease of fatty liver.","volume":"15","author":"Shen","year":"2013","journal-title":"Chin J Modern Med"},{"key":"R41-20260203","first-page":"82","article-title":"Changes and clinical significance of serum visfatin and adiponectin levels in type 2 diabetes patients with nonalcoholic disease of fatty liver.","volume":"18","author":"Sun","year":"2013","journal-title":"Zhejiang Pract Med"},{"key":"R42-20260203","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.11569\/wcjd.v22.i19.2763","article-title":"Clinical significance of plasma visfatin level in patients with non-alcoholic disease of fatty liver.","volume":"22","author":"Cai","year":"2014","journal-title":"World Chin J Digestol"},{"key":"R43-20260203","first-page":"335","article-title":"Effect of silymarin on serum adipocytokines in patients with nonalcoholic disease of fatty liver.","volume":"19","author":"Wei","year":"2014","journal-title":"Chinese Hepatology"},{"key":"R44-20260203","first-page":"98","article-title":"Study of the expression level of plasma visfatin and RBP4 and the correlation with insulin-resistance in patients with newly diagnosed type 2 diabetic mellitus combined with non-alcoholic disease of fatty liver.","volume":"12","author":"Wang","year":"2015","journal-title":"Chin Med Guides"},{"key":"R45-20260203","doi-asserted-by":"crossref","first-page":"e2630","DOI":"10.1097\/MD.0000000000002630","article-title":"Prediction of nonalcoholic fatty liver disease via a novel panel of serum adipokines.","volume":"95","author":"Jamali","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"R46-20260203","first-page":"827","article-title":"Association of NNMT gene polymorphism with serum visfatin and nonalcoholic disease of fatty liver.","volume":"18","author":"Chen","year":"2016","journal-title":"Zhejiang Clin Med"},{"key":"R47-20260203","first-page":"88","article-title":"The level and clinical significance of cytokines in patients with nonalcoholic disease of fatty liver.","volume":"23","author":"Zhou","year":"2017","journal-title":"Modern Instruments Med Treatment"},{"key":"R48-20260203","first-page":"1","article-title":"Study of apelin and visfatin in patients with non-alcoholic disease of fatty livers.","author":"Ge","year":"2018","journal-title":"Hebei Med Univ"},{"key":"R49-20260203","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000495215","article-title":"Association of circulating adipsin, visfatin, and adiponectin with nonalcoholic fatty liver disease in adults: a case-control study.","volume":"74","author":"Qiu","year":"2019","journal-title":"Ann Nutr Metab"},{"key":"R50-20260203","first-page":"965","article-title":"Levels and correlation analysis of serum adiponectin (APN) and visfatin in patients nonalcoholic disease of fatty liver and relevant factors.","volume":"24","author":"Qin","year":"2019","journal-title":"Modern Digest Intervention"},{"key":"R51-20260203","first-page":"1726","article-title":"Relationship between the serum levels of CK-18, visfatin and liver fibrosis indexes in patients with NAFLD.","volume":"41","author":"Yang","year":"2019","journal-title":"Hebei Med J"},{"key":"R52-20260203","first-page":"368","article-title":"Clinical Implications of sCD163 and IL-1 \u03b2mRNA in patients with nonalcoholic steatohepatitis.","volume":"23","author":"Fang","year":"2020","journal-title":"J Prac Hepatol"},{"key":"R53-20260203","first-page":"2376","article-title":"To investigate the levels of adipsin, visfatin and irisin in patients with nonalcoholic disease of fatty liver (NAFLD) and their correlation.","volume":"36","author":"Guo","year":"2020","journal-title":"J Pract Med"},{"key":"R54-20260203","first-page":"463","article-title":"Analysis of the value of serum \u03b3-GT, CHE, Apelin and visfatin in the diagnosis and treatment of patients with nonalcoholic disease of fatty liver.","volume":"18","author":"Hong","year":"2020","journal-title":"Chin J General Pract"},{"key":"R55-20260203","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.3390\/jcm10215194","article-title":"Relationship between adipokines and cardiovascular ultrasound parameters in metabolic-dysfunction-associated fatty liver disease.","volume":"10","author":"Ismaiel","year":"2021","journal-title":"J Clin Med"},{"key":"R57-20260203","first-page":"4677","article-title":"The correlation between RBP4, Visfatin, and non-alcoholic fatty liver disease in middle-aged and elderly populations.","volume":"43","author":"Zheng","year":"2023","journal-title":"Chin J Gerontol"},{"key":"R58-20260203","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.","volume":"363","year":"2004","journal-title":"Lancet"},{"key":"R59-20260203","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"R60-20260203","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1210\/clinem\/dgab641","article-title":"Association of MAFLD With diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China.","volume":"107","author":"Liang","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R61-20260203","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.13264","article-title":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. evidence from a systematic review and meta-analysis.","volume":"31","author":"Ballestri","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"R62-20260203","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cmet.2007.09.003","article-title":"Nampt\/PBEF\/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme.","volume":"6","author":"Revollo","year":"2007","journal-title":"Cell Metab"},{"key":"R63-20260203","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1111\/bph.13505","article-title":"Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine.","volume":"173","author":"Grolla","year":"2016","journal-title":"Br J Pharmacol"},{"key":"R64-20260203","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cmet.2011.08.014","article-title":"Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice.","volume":"14","author":"Yoshino","year":"2011","journal-title":"Cell Metab"},{"key":"R65-20260203","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.cmet.2015.04.002","article-title":"SIRT1-mediated eNAMPT secretion from adipose tissue regulates hypothalamic NAD+ and function in mice.","volume":"21","author":"Yoon","year":"2015","journal-title":"Cell Metab"},{"key":"R66-20260203","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cmet.2019.05.015","article-title":"Extracellular vesicle-contained eNAMPT delays aging and extends lifespan in mice.","volume":"30","author":"Yoshida","year":"2019","journal-title":"Cell Metab"},{"key":"R67-20260203","doi-asserted-by":"crossref","first-page":"10840","DOI":"10.12998\/wjcc.v10.i30.10840","article-title":"Role of visfatin in obesity-induced insulin resistance.","volume":"10","author":"Abdalla","year":"2022","journal-title":"World J Clin Cases"},{"key":"R68-20260203","first-page":"326","article-title":"Lipid profiles and serum visfatin concentrations in patients with type ii diabetes in comparison with healthy controls.","volume":"3","author":"Hajianfar","year":"2012","journal-title":"Int J Prev Med"},{"key":"R69-20260203","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/13813455.2021.1874997","article-title":"Visfatin level and gestational diabetes mellitus: a systematic review and meta-analysis.","volume":"127","author":"Jiang","year":"2021","journal-title":"Arch Physiol Biochem"},{"key":"R70-20260203","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-019-0455-5","article-title":"Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes.","volume":"11","author":"Zheng","year":"2019","journal-title":"Diabetol Metab Syndr"},{"key":"R71-20260203","first-page":"4322","article-title":"Adiponectin and visfatin may serve as diagnosis markers for metabolic syndrome in Uygur population.","volume":"7","author":"Chang","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"R72-20260203","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrendo.2015.117","article-title":"Physiological and pathophysiological roles of NAMPT and NAD metabolism.","volume":"11","author":"Garten","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"R73-20260203","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/sj.ijo.0800741","article-title":"Body mass index and percent body fat: a meta analysis among different ethnic groups.","volume":"22","author":"Deurenberg","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"R74-20260203","doi-asserted-by":"crossref","first-page":"e19835","DOI":"10.1371\/journal.pone.0019835","article-title":"Ethnic differences in body composition and obesity related risk factors: study in Chinese and white males living in China.","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"key":"R75-20260203","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"R76-20260203","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/dmrr.1201","article-title":"Visfatin in overweight\/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review.","volume":"27","author":"Chang","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"R77-20260203","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.","volume":"130","author":"Smith","year":"2020","journal-title":"J Clin Invest"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:01:02Z","timestamp":1770138062000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":74,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039613","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]}}}